Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Exclusion Criteria

• •Known distant metastatic disease or the tumor is deemed not surgically resectable
• •Established in a pain management clinic or has taken opioids regularly \>= 6 months
• •Known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin)
• •Known hypersensitivity to celecoxib, aspirin, other non-steroidal anti-inflammatory drug (NSAID)s, or sulfonamides
• •Uncontrolled hypertension defined as blood pressure (BP) \> 150 mmHg systolic or \> 90 mmHg diastolic on three consecutive reads, taken in one sitting despite optimal antihypertensive treatment
• •Patients with a known history of the following:
• •* Cerebrovascular accident (CVA), stroke, or cardiovascular thrombotic events (e.g. acute myocardial infarction).
• •* Chronic heart failure.
• •* Gastrointestinal bleeding, ulceration, peptic ulcer disease, or perforation of the stomach or intestines.
• •* Aspirin-sensitive asthma.
• •* Chronic kidney disease, stage 4 or 5
• •Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
• •The subject has uncontrolled, significant intercurrent or recent illness requiring systemic therapy, would preclude safe study participation, or is deemed clinically significant by the investigator
• •Known human immunodeficiency virus (HIV) infection with a detectable viral load within 6 months of the anticipated start of treatment.
• •* Note: Patients on effective anti-retroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial
• •Known chronic hepatitis B virus (HBV) or hepatitis C virus infection with a detectable viral load.
• •* Note: Patients with an undetectable HBV viral load on appropriate suppressive therapy are eligible. Patients with an undetectable hepatitis C virus (HCV) viral load on appropriate treatment are eligible
• •Subjects taking prohibited medications . A washout period of prohibited medications for a period of at least 5 half-lives or as clinically indicated should occur prior to the start of treatment